Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antiangiogenic therapies in colorectal cancer

Antiangiogenic therapies in colorectal cancer Angiogenesis is a very important step in the development of cancer. Several antiangiogenic biological agents have been studied during the past two decades for the treatment of colorectal cancer, both in adjuvant and metastatic settings. The first and most intensively studied is bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor. Since its approval in 2004, other antiangiogenic agents have been evaluated in clinical trials and some subsequently approved for the treatment of metastatic colorectal cancer such as aflibercept, ramucirumab, and regorafenib. In general, antiangiogenic agents show a modest efficacy in patients with metastatic colorectal cancer but not in the adjuvant setting. Also, there are no predictive biomarkers that could aid in selecting responsive patients. In this review we summarize the results of the completed large clinical trials investigating the efficacy of antiangiogenic therapies in colorectal cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Antiangiogenic therapies in colorectal cancer

Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/antiangiogenic-therapies-in-colorectal-cancer-9Z5S7dpO29
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag GmbH Austria
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0359-8
Publisher site
See Article on Publisher Site

Abstract

Angiogenesis is a very important step in the development of cancer. Several antiangiogenic biological agents have been studied during the past two decades for the treatment of colorectal cancer, both in adjuvant and metastatic settings. The first and most intensively studied is bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor. Since its approval in 2004, other antiangiogenic agents have been evaluated in clinical trials and some subsequently approved for the treatment of metastatic colorectal cancer such as aflibercept, ramucirumab, and regorafenib. In general, antiangiogenic agents show a modest efficacy in patients with metastatic colorectal cancer but not in the adjuvant setting. Also, there are no predictive biomarkers that could aid in selecting responsive patients. In this review we summarize the results of the completed large clinical trials investigating the efficacy of antiangiogenic therapies in colorectal cancer.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Oct 25, 2017

References

  • Annual report to the nation on the status of cancer, 1975–2012, featuring the increasing incidence of liver cancer
    Ryerson, AB; Eheman, CR; Altekruse, SF
  • -
    Masi, G; Vasile, E; Loupakis, F
  • Cancer statistics
    Siegel, RL; Miller, KD; Jemal, A
  • Role of angiogenesis in human tumor dormancy: Animal models of the angiogenic switch
    Naumov, GN; Akslen, LA; Folkman, J
  • Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group
    Figueredo, A; Charette, ML; Maroun, J
  • Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    André, T; Boni, C; Mounedji-Boudiaf, L
  • Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon : results of NBSAP protocol C‑08
    Allegra, CJ; Yothers, G; O’Connell, MJ
  • Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): A phase 3 randomized controlled trial
    Gramont, A; Cutsem, E; Schmoll, HJ
  • Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): An open-label, randomized phase 3 trial
    Kerr, RS; Love, E; Johnstone, E
  • Defective mismatch repair and benefit from bevacizumab for colon cancer: Findings from NSABP C‑08
    Pogue-Geile, K; Yothers, G; Taniyama, Y
  • PD-1 blockade in tumors with mismatch-repair deficiency
    Le, DT; Uram, JN; Wang, H
  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz, H; Fehrenbacher, L; Novotny, W
  • Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results from the BICC-C study
    Fuchs, CS; Marshall, J; Barrueco, J
  • Treatment of colorectal cancer with and without bevacizumab: A phase III study
    Stathopoulos, GP; Batziou, C; Trafalis, D
  • Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: Final results for first-line treatment from the ITACa randomized clinical trial
    Passardi, A; Nanni, O; Tassinari, D
  • Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
    Saltz, LB; Clarke, S; Diaz-Rubio, E
  • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Oncology Group Study E3200
    Giantonio, BJ; Catalano, PJ; Meropol, NJ
  • Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial
    Kabbinavar, FF; Schulz, J; McCleod, M
  • Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: A systematic review and meta-analysis
    Botrel, TE; Clark, LG; Paladini, L
  • Second-line systemic therapy for metastatic colorectal cancer
    Mocellin, S; Baretta, Z; Roqué, I; Figuls, M
  • Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomized phase 3 trial
    Bennouna, J; Sastre, J; Arnold, D
  • Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEPYP trial
    Masi, G; Salvatore, L; Boni, L
  • Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
    Cutsem, E; Tabernero, J; Lakomy, R
  • A VELOUR post hoc subset analysis: Prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI
    Chau, I; Joulain, F; Iqbal, SU
  • Oxaliplatin and 5‑FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: The AFFIRM study
    Folprecht, G; Pericay, C; Saunders, MO
  • Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomized, double-blind, multicentre, phase 3 study
    Tabernero, J; Yoshino, T; Cohn, AL
  • Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomized, placebo-controlled, phase 3 trial
    Grothey, A; Cutsem, E; Sobrero, A
  • Markers for response for the Antiangiogenic Agent Bevacizumab
    Lambrechts, D; Lenz, HJ; Haas, S
  • Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
    Dienstmann, R; Vermeulen, L; Guinney, J